To scroll text in this page

Global Navigation

About Astellas

Start of the main text

History

History of the Former Yamanouchi Pharmaceutical Co., Ltd.
1923

Kenji Yamanouchi founded Yamanouchi Yakuhin Shokai in Osaka.

Changed the name to Yamanouchi Pharmaceutical Co., Ltd. in 1940, Moves the head office to Tokyo in 1942

Photo of Yamanouchi Yakuhin Shokai around the time of foundation
1970

Launched antibiotic drug "Josamycin"

1981

Launched "Perdipine," an agent for the treatment of hypertension

1985

Launched "Gaster," an H2 reseptor antagonist diseases/gastritis
Currently sold in more than 100 countries

1986

Established Yamanouchi Ireland Co., Ltd. in Europe
The first overseas production base for active pharmaceutical ingredients

1989

Tsukuba laboratory completed

1990

Acquired the pharmaceutical division of Royal Gist Brocades (Netherlands)

Exterior view of Royal Gist Brocades
1993

Launched "Harnal"
Currently sold in more than 90 countries

Photo of “Harnal”, an agent to alleviate urination disorder
1994

Established Shenyang Yamanouchi Pharmaceutical Co., Ltd. in China

2000

Launched "Lipitor," an agent to treat hypercholesterolemia

2001

Established Yamanouchi Pharma America, Inc. in the U.S.
Sales base of the company in the U.S.

2004

Launched "Vesicare," an agent for overactive bladder treatment, in Europe

Launched in the U.S. as well in 2005

OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.

History of the Former Fujisawa Pharmaceutical Co., Ltd.
1894

Tomokichi Fujisawa founded Fujisawa Shoten in Osaka

Photo of Fujisawa Shoten when founded
1897

Launched "Fujisawa Camphor" as a home-use insect repellent

Photo of a package of Fujisawa Camphor sold in the Taisho Era
1943

Changed the company name to Fujisawa Pharmaceutical Co., Ltd.

1964

Central Laboratory completed

1971

Launched "Cefamezin," an antibiotic for injections
Proceeds to market it worldwide.

1977

Established Fujisawa Pharmaceutical Corp. in the U.S.
The company's first business base in the U.S.

1979

Opened a London Office, the company's first business base in Europe

1983

Tsukuba Laboratory completed

1991

Established Fujisawa Europe GmbH in Germany

1993

Launched immunosuppressant "Prograf"
Currently sold in about 80 countries

Photo of immunosuppressant “Prograf”
1998

Restructured the business in the U.S., founds Fujisawa Healthcare, Inc.

1999

Launched "Protopic," an agent to treat atopic dermatitis
Currently sold in about 60 countries

Photo of “Protopic,” an agent to treat atopic dermatitis
2004

OTC businesses of both companies were integrated in October 1, 2004 to form Zepharma Inc.

Apr. 1, 2005 Astellas Pharma Inc. was established

Photo of a scene from the joint press release
History of Astellas Pharma Inc.
May 2005

Launched "Mycamine," an intravenous candin antifungal agent

Apr. 2006

Launched "Vaprisol," an agent for the treatment of hyponatremia, in the U.S.

Sold Zephama shared to Daiichi Sankyo Co., Ltd.

Jun. 2006

Launched "Vesicare", an agent for overactive bladder treatment, in Japan

Photo of “Vesicare,” an agent for overactive bladder treatment
Jun. 2007

Launched immunosuppresant "Advagraf" in Europe

Nov. 2007

Acquired Agensys, Inc

Oct. 2008

Completed the New Buildings in the Tsukuba Research Center

Apr. 2009

Launched "Bonoteo Tablets" in Japan for the Osteoporosis Treatment

Nov. 2009

Launched "VIBATIV (telavancin)" in the United States

Jan. 2010

Launched "Symbicort Turbuhaler" in Japan for the treatment of Adult Bronchial Asthma

Jun. 2010

Acquired OSI Pharmaceuticals

Sep. 2011

Launched "Betanis Tablet" in Japan for the treatment of overactive bladder (OAB)

Photo of Betanis Tablet
Jun. 2012

Launched "DIFICLIR" in Europe for the treatment of adults with Clostridium difficile infections (CDI)
Launched "Kiklin Capsules" in Japan for the treatment for Hyperphosphatemia

Jul. 2012

Launched "Regnite Tablets" in Japan for Restless Legs Syndrome

Sep. 2012

Launched "XTANDI (enzalutamide)" in the U.S. for Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated with Docetaxel

Photo of XTANDI (enzalutamide)
Oct. 2012

Launched "Gonax (Degarelix Acetate)" for Subcutaneous Injection in Japan for Treating Prostate Cancer
Launched "MYRBETRIQ (mirabegron)" in the U.S. for the treatment of overactive bladder (OAB)

Jan. 2013

Launched "ARGAMATE" in Japan for the treatment of Hyperkalemia

Mar. 2013

Launched "Cimzia (certolizumab pegol)" in Japan for the treatment of adult patients with rheumatoid arthritis

Apr. 2013

Relocated Global HQ building in Tokyo

Photo of Global HQ building
Jun. 2013

Launched "Acofide" in Japan for Treating Functional Dyspepsia

Aug. 2013

Launched "ASTAGRAF XL (tacrolimus extended-release capsules)" in the U.S.

Apr. 2014

Launched "Suglat Tablets", a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes

May 2014

Launched "XTANDI (enzalutamide) Capsules" in Japan for Prostate Cancer Treatment

Main Text end
Local Navigation
Local Navigation end
Related Links